source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable3 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
external sourcelocator
title:FDA approval materials, CMS coverage decisions, and sponsor discontinuation notices
imported
2026-05-06T03:57:47.141142+00:00
extraction mode
manual_curation
authors
reviewer:will-blair-bot
Caveats
No source-specific caveats are recorded.
Aducanumab approval did not establish a stable clinical translation pathway for anti-amyloid therapy because the program was discontinued after contested evidence and restricted uptake.
events
vev_44f1a5f04c58fcf8finding.notedRegulatory source reg-fda-aducanumab changed tracked source fields: source locator changed from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information to https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information. Review whether this affects the linked finding scope, trial table, or decision brief; source metadata alone does not change the claim.
reviewer:will-blair-bot · 2026-05-06
vev_93f4fe25cdc8802efinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_d3ad8fcddb85049efinding.reviewedRegulatory history is factual, but its implication for the anti-amyloid class remains contested.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_1d0faeb172ca1b81finding.noteReview regulatory source record delta for reg-fda-aducanumab from run sir_4c5bbc2d54bb56be
applied · reviewer:will-blair-bot · 2026-05-06
vpr_3ac95fdf616023a7finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_e242b8fa10d4df8cfinding.reviewRegulatory history is factual, but its implication for the anti-amyloid class remains contested.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation rows are attached.